Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that wo...
主要な著者: | Foxwell, B, Andreakos, E, Brennan, F, Feldmann, M, Smith, C, Conron, M |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2003
|
類似資料
-
Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.
著者:: Sumariwalla, P, 等
出版事項: (2009) -
Cytokines and anti-cytokine biologicals in autoimmunity: present and future.
著者:: Andreakos, E, 等
出版事項: (2002) -
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
著者:: Foxwell, B, 等
出版事項: (2000) -
Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist.
著者:: Neve, R, 等
出版事項: (1996) -
Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
著者:: Brennan, F, 等
出版事項: (1995)